Prelude Therapeutics Inc
Nasdaq · Healthcare · Pharmaceutical Preparations · Wilmington, DE
PRLD chart
What traders are saying about $PRLD
Latest postsPrelude Therapeutics Inc news
- Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Yahoo Finance ·
- Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
marketbeat.com ·
- PRLD Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 4.25% - Earnings Expansion Phase
https://www.dars.gov.et/ ·
- Prelude Therapeutics secures Lilly deal. Citizens targets Prelude Therapeutics stock at USD 6.00
ad-hoc-news.de ·
- Prelude Therapeutics to Participate in the Chardan Healthcare Conference
Yahoo Finance ·
- Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Yahoo Finance ·
- Eli Lilly (LLY) Reported One Year Steroid Free Control In Difficult IBD
Yahoo Finance ·
- Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
stocktwits.com ·
- Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Yahoo Finance ·
- Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Yahoo Finance ·
- Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
stocktwits.com ·
Prelude Therapeutics Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | – | – |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M |
| Diluted EPS | $-1.29 | $-1.68 | $-2.02 | $-2.44 |
| Total assets (year end) | $141.3M | $175.5M | $277.7M | $220.5M |
| Cash and equivalents (year end) | $35.3M | $12.5M | $25.3M | $30.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Prelude Therapeutics Inc
- Ticker
- PRLD (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Wilmington, DE
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1678660
- Former names
- Prelude Therapeutics Inc.
Frequently asked questions
What exchange is Prelude Therapeutics Inc listed on?
Prelude Therapeutics Inc trades on the Nasdaq under the ticker symbol PRLD.
What industry is Prelude Therapeutics Inc in?
Prelude Therapeutics Inc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Prelude Therapeutics Inc headquartered?
Prelude Therapeutics Inc's business address on file with the SEC is in Wilmington, DE.
When does Prelude Therapeutics Inc's fiscal year end?
Prelude Therapeutics Inc's fiscal year ends on December 31.
How much revenue did Prelude Therapeutics Inc report?
Prelude Therapeutics Inc reported $12.1M in revenue for calendar year 2025, according to its SEC filings.